Trial Profile
A Single Center, Open Label, Longitudinal Single Arm Study to Compare the Efficacy and Safety of Prophylactic Famciclovir 500 mg b.d. in HIV Positive Adults With Recurrent Genital Herpes.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Mar 2013
Price :
$35
*
At a glance
- Drugs Famciclovir (Primary)
- Indications Herpes genitalis
- Focus Adverse reactions; Therapeutic Use
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Jul 2010 New trial record